CTX-310

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameCTX-310
Drug Alias NameCTX-310CTX310
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionAngiopoietin like 3 inhibitors
TargetsAngiopoietin like 3
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaSitosterolemiaHomozygous familial hypercholesterolemia +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaSitosterolemiaHomozygous familial hypercholesterolemia +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A